The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models

@article{Clmenson2012TheVD,
  title={The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models},
  author={C{\'e}line Cl{\'e}menson and Erwan Benjamin Jouannot and Ana Merino-Trigo and Chantal Rubin-Carrez and Eric Deutsch},
  journal={Investigational New Drugs},
  year={2012},
  volume={31},
  pages={273-284}
}
Targeting tumor vasculature is an emerging strategy in cancer treatment. Promising results have been shown in preclinical studies when vascular disrupting agents (VDAs) are used in combination with other anticancer therapies. Because radiation therapy with concurrent cisplatin or cetuximab has become standard treatment for patients with locally advanced head and neck squamous cell carcinoma (HNSCC), we investigated whether the VDA ombrabulin (AVE8062) could improve the antitumor activity of… CONTINUE READING